Founded in 2015, Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company built around a patient-centered approach to cancer research. From its Colleen Connor Cancer Research Lab, the company develops local treatments for people with metastatic cancer affecting bone, including the investigational therapy ZetaMet, which is designed to address tumors while supporting bone repair.
U.S. FDA Breakthrough Designation for ZetaMet™ (Zeta-BC-003)
Compliance program
U.S. FDA Breakthrough Device Designation for ZetaFuse™
Compliance program
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV
BeyondSpringFounded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.NEW YORK, NY
Tactical TherapeuticsFounded in 2005 by cancer scientist and patent attorney Rashida A. Karmali, Tactical Therapeutics is a clinical-stage biopharmaceutical company built around her long career in cancer research, drug development, and intellectual property law. The company develops CTO, an oral therapy designed to reach the brain, for patients with glioblastoma and other cancers that have resisted treatment. Karmali has authored more than 100 scientific publications and holds eight U.S. patents alongside more than 75 international patents.NEW YORK, NY
Sermonix PharmaceuticalsFounded in late 2014 by women’s-health researcher David Portman, MD, Columbus-based Sermonix Pharmaceuticals is a privately held biopharmaceutical company developing targeted oncology therapies for women, with a precision-medicine focus. Its lead investigational therapy, oral lasofoxifene, is being studied in the ELAINE clinical programs for ESR1-mutated, hormone receptor-positive/HER2-negative advanced or metastatic breast cancer. Sermonix also conducts patient-centered EQUALS surveys on treatment experiences, sexual health, and quality of life in metastatic breast cancer.COLUMBUS, OH